News and Updates

The true story of how Tzield (teplizumab), the first disease-modifying therapy approved for use in delaying type 1 diabetes (T1D) onset, made it to market.

Leading researchers gathered for the ATTD meeting, which featured more than 50 studies presented by Breakthrough T1D-funded researchers.

This year’s Advanced Technologies & Treatments for Diabetes (ATTD) meeting, which will be held on March 6-9, will have 50 Breakthrough T1D-funded presenters.

With an investment from the Breakthrough T1D T1D Fund, vTv Therapeutics will run a phase III clinical trial of cadisegliatin (TTP399), an adjunct therapy to insulin.

Leading researchers gathered in Long Beach, California, for the 16th annual meeting of the Network for Pancreatic Organ Donors with Diabetes (nPOD).

Leading scientists will gather for the annual meeting of the Network for Pancreatic Organ Donors with Diabetes (nPOD), held February 19-22 in California.

Breakthrough T1D funded 3 projects to address eating disorders + T1D and a study that presents the risks of T1D eating disorders and current barriers to safe treatment.

In 2023 alone, there have been several important papers published on disease-modifying therapies (DMT) for type 1 diabetes. This blog explains everything you need to know about several DMTs.

Breakthrough T1D and ISAPD announce the recipients of the 2023 fellowships. These fellowships will help bring the best in T1D care to new communities around the world.

A guest post from Breakthrough T1D's social media manager, Grace Bennett, about life-with-T1D lessons she's learned in 19+ years.